Funding profile · Genomics software

Spiral Genetics

Form D filings across five years account for $3.66 million. The company was sold in January 2017, bought back by its founder in 2019, and has filed nothing since May 2016.

$3.66MTotal sold across all Form D filings, 2012 to 2016
$3.22MThe 2013 equity round, sold in full to 12 investors
$350KConvertible debt sold 2015 to 2016, 2 investors
$5.0MRaised before the 2017 sale, per Forbes in 2019

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Jul 2012 Convertible promissory notes $90,000 sold of $300,000 offered 3 Form D
Feb 2013 Equity, reported as a Series A led by DFJ $3,216,000 sold of $3,216,000 offered 12 Form D and reporting
Aug 2015 to May 2016 Convertible debt, amended three times $350,000 sold, raised from $200,000 1, then 2 Form D and 3 amendments
Jan 2017 Acquisition by Omicia, Inc. Undisclosed None Company release
Early 2019 Reacquisition by the founder, then Y Combinator W19 Undisclosed Y Combinator Independent reporting
After 2019 A raise the founder said was starting Nothing on record None No filing found

What the filings show

Spiral Genetics, Inc. · Form D · filed Aug 10, 2012

First sale
Jul 7, 2012
Security
Convertible notes
Offered
$300,000
Sold
$90,000 · $210,000 remaining
Investors
3 · average $30,000
To officers
$120,000 of the offering, for payments to officers, directors and promoters
Exemption
Rule 506
Related persons
Alindrina Mangubat (officer, director); Becky Drees (officer, director); Jeremy Bruestle (officer)
Filing
SEC EDGAR, CIK 0001555798

Spiral Genetics, Inc. · Form D · filed Mar 11, 2013

First sale
Feb 27, 2013
Security
Equity
Offered
$3,216,000
Sold
$3,216,000 · nothing remaining
Investors
12 · average $268,000
To officers
$475,000, about 15 percent of the round
Exemption
Rule 506
Related persons
Alindrina Mangubat (officer, director); Becky Drees (officer, director); Jeremy Bruestle (officer)
Filing
SEC EDGAR, CIK 0001555798, incorporated 2009 in Delaware

Spiral Genetics, Inc. · Form D · filed Oct 2, 2015

First sale
Aug 27, 2015
Security
Convertible debt
Offered
$200,000
Sold
$200,000 · nothing remaining
Investors
1 · minimum check $200,000
Exemption
Rule 506(b)
Related persons
Alindrina Mangubat (officer, director); Jeremy Bruestle (director); Richard Jacroux (director)
Filing
SEC EDGAR, CIK 0001555798

Spiral Genetics, Inc. · Form D/A · filed May 10, 2016, the third amendment

First sale
Aug 27, 2015, unchanged
Offered
$350,000, raised from $200,000 in three 2016 amendments
Sold
$350,000 · nothing remaining
Investors
2 · minimum check lowered to $50,000
Exemption
Rule 506(b)
Related persons
Alindrina Mangubat (officer, director); Jeremy Bruestle (director); Richard Jacroux (director)
Filing
SEC EDGAR, CIK 0001555798

Reading the filings

  1. The 2013 round was bigger than the headline and broader than one fund.Press called it a $3 million Series A from DFJ. The filing reports $3,216,000 offered and $3,216,000 sold to 12 investors, an average of $268,000 each. A lead fund does not need 11 co-investors, so angels or a syndicate came in alongside DFJ.
  2. A meaningful slice went to insiders.The 2013 filing earmarks $475,000 of gross proceeds for payments to officers, directors and promoters, about 15 percent of the round. The 2012 note filing earmarks $120,000 of a $300,000 offering for the same purpose, but only $90,000 of it was ever sold.
  3. The last financing was a bridge that kept being extended.One offering opened on August 27, 2015 at $200,000 from a single investor, then was amended three times in four months: $250,000 on January 11, 2016, $300,000 on February 11, and $350,000 on May 10, when a second investor appears and the minimum check drops to $50,000. Convertible debt topped up in $50,000 increments is not growth capital. The acquisition was announced eight months later.
  4. The cap table team changed between the equity round and the bridge.The 2012 and 2013 filings list co-founder Becky Drees as an officer and director and Jeremy Bruestle as an officer. By October 2015 Drees no longer appears, Bruestle is a director only, and a new director, Richard Jacroux, has joined. These lists are not a full board roster, but the change is on the record.
  5. Filed totals sit below reported totals, and the 2019 relaunch left no trace at all.Form Ds account for $3,656,000 between 2012 and 2016. Mangubat told Chemical and Engineering News in 2013 that total financing stood at $3.7 million; Forbes reported $5 million before the 2017 sale. Financings under Section 4(a)(2) produce no Form D, so early angel money would not appear. Nothing has been filed under CIK 0001555798 since May 10, 2016, including for the raise the founder said was starting in 2019.

Commercial signals

Signal Detail Source type
Revenue “Low hundreds of thousands” as of October 2016, stated by the CEO. No later figure published. Company-stated
Pricing Roughly $700 to $800 per whole human genome in 2014, with volume pricing down to about $300 to $400. Trade press
Named users UC Davis, UC Irvine, Melbourne and Montreal in 2014; a Baylor pilot in 2015. Trade press
Exit Acquired by Omicia, Inc. of Oakland, Jan 23, 2017, terms undisclosed. Omicia renamed itself Fabric Genomics that March. Company release
Reversal The founder reacquired the company in early 2019, took it through Y Combinator W19, and announced a Microsoft Azure partnership that March. Independent
Trademark Registration 4026641 cancelled Mar 25, 2022 for failure to file a Section 8 declaration. Public record
Intellectual property BioGraph released on GitHub Jul 14, 2021 under BSD 2-clause, last commit Aug 22, 2023. Patents remain assigned to the company. Public record
Company status Y Combinator records it Inactive, batch W19, team size 7, checked Sep 23, 2026. Its domain now serves an unrelated gambling site. Public record

What to watch

  • Any Form D under CIK 0001555798. Nothing in more than ten years.
  • Assignment of the patents to a new owner, the clearest sign the assets moved.
  • Activity on the BioGraph repository, dormant since August 2023.

The Spiral Genetics story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Haplotype Labs: Shared investor: Form D. Healthcare Venture Capital. A one person software company founded by the architect who built 23andMe’s platform, selling labs and prevention clinics a hosted way to run polygenic risk models
  • Pirouette Pharma: Shared investor: Form D. Healthcare Venture Capital. A disk-shaped, push-button auto-injector built by three engineers who met running a student rocket lab, now paired with old drugs on abbreviated FDA pathways
  • Sohar Health: Shared investor: Form D. Healthcare Venture Capital. An API that tells a behavioral health clinic, in about six seconds, whether a patient’s insurance will actually pay
  • Tradewind BioScience: Shared investor: Form D. Healthcare Venture Capital. A two person antibody company built around EGFL6, a secreted protein that ovarian tumors make and healthy adult tissue mostly does not

Sources

  1. Public recordForm D, Spiral Genetics, Inc.SEC · Aug 10, 2012
  2. Public recordForm D, Spiral Genetics, Inc.SEC · Mar 11, 2013
  3. Public recordForm D and three amendments, Spiral Genetics, Inc.SEC · Oct 2, 2015 to May 10, 2016
  4. Public recordTrademark status, SPIRAL GENETICS, registration 4026641USPTO TSDR · accessed Sep 23, 2026
  5. Public recordY Combinator directory record and GitHub repositoriesAccessed Sep 23, 2026
  6. IndependentSpiral Genetics scores $3M VC round from DFJFierce Biotech · Mar 13, 2013
  7. InterviewHow Adina Mangubat built a software company for analyzing DNAMixergy · Oct 21, 2016
  8. IndependentSeattle’s Spiral Genetics acquired by OmiciaGeekWire · Jan 23, 2017
  9. IndependentA 32-Year-Old CEO Relaunches Her Genetic Data Mining CompanyForbes, Ellie Kincaid · Mar 15, 2019
  10. InterviewSpiral Genetics and its young CEO prepare for a fund-raising roundFlynn’s Harp · May 2, 2019
  11. CompanyOmicia Acquires Bioinformatics Innovator Spiral GeneticsBusiness Wire · Jan 23, 2017

Compiled from SEC, USPTO and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date. Financings exempt under Section 4(a)(2) produce no Form D. Healthcare Venture Capital Fund holds no position in Spiral Genetics. This page is not an offer to sell or a recommendation to buy any security.